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Recently, DNA-topoisomerase II inhibitors, such as epipodophyllotoxins, anthracyclines, carboplatin, mitoxantrone, razoxane and bimolane have been increasingly reported as leukemogenic agents in patients with TRAL. [4] [5] [6] [7] [8] [9] [10] [11] [12] Acute leukemias related to the use of DNA-topoisomerase II inhibitors have a shorter latency period without myelodysplastic prodromes and are clinically and cytogenetically similar to the primary leukemias. 5 It has been suggested that leukemia following the use of DNA-topoisomerase II inhibitors may be associated with chromosomal aberrations, ascribable to the mechanism of action of these drugs. 10 For example, anthracyclines and mitoxantrone appear to allow formation of proteinassociated double-strand breaks, but prevent DNA-topoisomerase II from completing its cycle with re-ligation of the broken strands. 13 Indeed, the present case is closely related to this second pattern of TRAL. Mitoxantrone is a completely synthetic DNA intercalator based on the anthracenedione structure, closely related to the anthracyclines. 13 It is used in several polychemotherapy regimens for hematological malignancies and solid tumors.
Most patients developing TRAL have a pre-existing malignancy and the secondary leukemia may simply be the expression of a neoplastic diathesis, on which the radiochemotherapy may act as an accelerating factor. Interestingly, our patient had no history of exposure to known leukemogenic risk factors, or personal or family history of malignancy. In this respect, although an excessive prevalence of MS has been reported in mothers of children with acute lymphatic leukemia, MS is not considered a predisposing condition for neoplasia.
14 Although TRAL has been reported in a few patients affected by advanced psoriasis treated with razoxane or bimolane, 9, 10 this is, to our knowledge, the first case of TRAL related to the use of mitoxantrone as single agent for a non-neoplastic disease. Essential thrombocythemia (ET) is a chronic myeloproliferative disorder, characterized by the proliferation of a pluripotent cell, leading to an increase in the number of platelets. Since ET does not have a distinct cytogenetic or molecular marker, it has been defined by means of negative criteria, one of which is the lack of the Ph 1 chromosome and/or BCR/ABL rearrangement. However, adult patients have been described with a disease resembling ET, but showing Ph 1 chromosome and/or BCR/ABL rearrangement. [1] [2] [3] [4] [5] We report a girl with a Ph 1 -positive and BCR/ABL-positive CMD presenting as ET. A 5.-year-old female, without previous relevant history, came to our hospital because of fever up to 39.5°C, abdominal pain, vomiting, and diarrhea. She was diagnosed as having intestinal infection and these symptoms subsided in 48 h. Physical examination showed splenomegaly 3 cm below the left costal margin and hepatomegaly 1 cm below the costal margin, with no lymphadenopathies or other abnormal signs. Peripheral blood counts showed: hemoglobin 13.6 g/dl, WBC 8.4 × 10 9 /l (57% neutrophils, 38% lymphocytes, 5% basophils) and 2200 × 10 9 /l platelets. Neutrophil alkaline phosphatase score was 40/400, ferritin 12 ng/ml, transferrin 325 g/dl, transferrin saturation 18%, and all other biochemical parameters were normal. The bone marrow aspirate showed a marked megakaryocytic hyperplasia (many megakaryocytes, small in size, with hypolobulated nuclei), aggregates of platelet debris and 3-5% blast; the myeloid and erythroid series were conserved. The study of platelet aggregation showed a decrease of the aggregation with collagen, adrenalin, arachidonic acid and adenosine diphosphate, and was normal with ristocetin. Three months later, the patient still had 3000 × 10 9 /l platelets, WBC 12.2 × 10 9 /l (63% neutrophils, 25% lymphocytes, 4% monocytes, 5% basophils, 3% eosinophils) and hemoglobin 13.4 g/dl with no treatment, and began treatment with hydroxyurea.
Cytogenetic analysis showed a t(9;22). The RT-PCR analysis, performed using published methods, 6 revealed the presence of P210 (b2a2 junction) ( Figure 1a ) and P190 (Figure 1b) type of BCR/ABL mRNAs in peripheral blood and bone marrow cells. The vast majority of CML cases exhibit a break of the BCR gene in a 5.8 kb region named M-BCR which, depending on the BCR gene breakpoint, produces two types of mRNA by the junction of exon 3 of the BCR gene to exon 2 of the ABL gene (b3a2 junction) or of BCR exon 2 to exon 2 of ABL (b2a2 junction) and both chimeric mRNAs encode a 210 kDa protein (P210). In our case Southern blot analysis confirmed the BCR/ABL rearrangement with a breakpoint in the M-BCR region (data not shown).
Recently, Cervantes et al 1 have suggested an association between b3a2 junction and CML with thrombocythemia, in contrast to Kwong 7 who has suggested that this association may be fortuitous. Our case showed the b2a2 junction confirmed by Southern blot analysis and could support the last hypothesis. In addition to P210 mRNA, there was a P190 BCR/ABL hybrid mRNA. The presence of low levels of mRNA of the P190 protein in most cases of P210 BCR/ABL positive patients has been recently described. 6 Sporadic cases have been reported of adult patients with thrombocythemia higher than 1000 × 10 9 /l and moderate leukocytosis, who presented Ph 1 chromosome and/or BCR/ABL rearrangement. [1] [2] [3] [4] [5] To our knowledge, the case described here is the first pediatric patient with a Ph 1 -positive CMD presenting as ET.
These cases might be considered as at the initial stage of CML, although from the clinical point of view would fit with real ETs with a Philadelphia chromosome. However, the Polycythemia Vera Study Group establishes the presence of t(9;22) of the BCR/ABL hybrid gene as an exclusion criteria for the ET diagnosis. It has been suggested that Ph 1 positive thrombocythemias have clinicopathological characteristics different from those of CML, mainly higher frequency in females,
